ROCKVILLE, MD and SEOUL, KOREA--(Marketwire - July 21, 2010) - The emergence and spread of drug-resistant mycobacterium tuberculosis (TB) threatens global TB control efforts, and there is an urgent need for new diagnostic tests that rapidly identify drug sensitivity profiles of TB strains. To help address these concerns, Seegene today introduced Anyplex™ MDR-TB Screening Test, the first real-time PCR molecular diagnostic capable of simultaneous detection of TB and genetic mutations leading to multi-drug resistant TB (MDR-TB) within four hours.
